Alterations in SARS-CoV-2 Omicron and Delta peptides presentation by HLA molecules.


Journal

PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425

Informations de publication

Date de publication:
2022
Historique:
received: 01 03 2022
accepted: 08 04 2022
entrez: 3 5 2022
pubmed: 4 5 2022
medline: 4 5 2022
Statut: epublish

Résumé

The T-cell immune response is a major determinant of effective SARS-CoV-2 clearance. Here, using the recently developed T-CoV bioinformatics pipeline (https://t-cov.hse.ru) we analyzed the peculiarities of the viral peptide presentation for the Omicron, Delta and Wuhan variants of SARS-CoV-2. First, we showed the absence of significant differences in the presentation of SARS-CoV-2-derived peptides by the most frequent HLA class I/II alleles and the corresponding HLA haplotypes. Then, the analysis was limited to the set of peptides originating from the Spike proteins of the considered SARS-CoV-2 variants. The major finding was the destructive effect of the Omicron mutations on PINLVRDLPQGFSAL peptide, which was the only tight binder from the Spike protein for HLA-DRB1*03:01 allele and some associated haplotypes. Specifically, we predicted a dramatical decline in binding affinity of HLA-DRB1*03:01 and this peptide both because of the Omicron BA.1 mutations (N211 deletion, L212I substitution and EPE 212-214 insertion) and the Omicron BA.2 mutations (V213G substitution). The computational prediction was experimentally validated by ELISA with the use of corresponding thioredoxin-fused peptides and recombinant HLA-DR molecules. Another finding was the significant reduction in the number of tightly binding Spike peptides for HLA-B*07:02 HLA class I allele (both for Omicron and Delta variants). Overall, the majority of HLA alleles and haplotypes was not significantly affected by the mutations, suggesting the maintenance of effective T-cell immunity against the Omicron and Delta variants. Finally, we introduced the Omicron variant to T-CoV portal and added the functionality of haplotype-level analysis to it.

Identifiants

pubmed: 35502206
doi: 10.7717/peerj.13354
pii: 13354
pmc: PMC9055995
doi:

Substances chimiques

HLA-DRB1 Chains 0
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e13354

Informations de copyright

© 2022 Nersisyan et al.

Déclaration de conflit d'intérêts

Stepan Nersisyan is an employee of Armenian Bioinformatics Institute (ABI). Alexander Tonevitsky is an employee of Art Photonics GmbH.

Références

Blood. 2020 Dec 17;136(25):2905-2917
pubmed: 33331927
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Yonsei Med J. 2007 Feb 28;48(1):11-23
pubmed: 17326240
NPJ Vaccines. 2021 Feb 22;6(1):28
pubmed: 33619260
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
iScience. 2022 Mar 18;25(3):103934
pubmed: 35194575
Front Immunol. 2022 Feb 03;13:769900
pubmed: 35185875
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
Clin Exp Immunol. 2021 Sep;205(3):363-378
pubmed: 34061349
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Immunity. 2018 Feb 20;48(2):202-213
pubmed: 29466753
Nucleic Acids Res. 2022 Jan 7;50(D1):D883-D887
pubmed: 34396391
Cell Syst. 2022 Feb 16;13(2):143-157.e3
pubmed: 34637888
Front Immunol. 2022 Jan 18;12:764949
pubmed: 35116022
EClinicalMedicine. 2021 Oct;40:101099
pubmed: 34490415
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Clin Pract. 2021 Oct 21;11(4):778-784
pubmed: 34698149
BMC Bioinformatics. 2017 May 30;18(1):284
pubmed: 28558647
J Immunol Res. 2018 Feb 25;2018:3174868
pubmed: 29682588
Emerg Microbes Infect. 2022 Dec;11(1):277-283
pubmed: 34951565
Clin Immunol. 2020 Oct;219:108572
pubmed: 32810602

Auteurs

Stepan Nersisyan (S)

Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Institute of Molecular Biology, The National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia.
Armenian Bioinformatics Institute (ABI), Yerevan, Armenia.

Anton Zhiyanov (A)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Maria Zakharova (M)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Irina Ishina (I)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Inna Kurbatskaia (I)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Azad Mamedov (A)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Alexei Galatenko (A)

Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, Russia.

Maxim Shkurnikov (M)

Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.

Alexander Gabibov (A)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Alexander Tonevitsky (A)

Faculty of Biology and Biotechnology, HSE University, Moscow, Russia.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Art Photonics GmbH, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH